Assistant Professor, Medicine, Medical College of Wisconsin
Hematology
Dr. Ehab Atallah, MD
|
|
Give Review
Ehab Atallah practices Hematology. He went to medical school at Wayne State University School of Medicine. Wayne State University School of Medicine has a rank of 63 in research and a 85 in primary care He over the years received 1 awards: "CMS Meaningful Use Stage 1 Certification". Ehab Atallah is a published physician. He published 33 publications, including: 'Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled,...' Dr. Ehab Atallah accepts Medicare payments and is listed with Medicare.gov.
Publications
- Quality of Life and Long-Term Therapy in Patients with Chronic Myeloid Leukemia.
- Efficacy of ruxolitinib on hepatomegaly in patients with myelofibrosis.
- Large Granular Lymphocytic Leukemia Presenting Late After Solid Organ Transplantation: A Case Series of Four Patients and Review of the Literature.
- Myelodysplastic Syndromes in the United States: an update for clinicians.
- Treatment of Older Patients with High-Risk Myelodysplastic Syndromes (MDS): The Emerging Role of Allogeneic Hematopoietic Stem Cell Transplantation (Allo HSCT).
- Impact of donor source on hematopoietic cell transplantation outcomes for patients with myelodysplastic Syndromes (MDS).
- Emerging drugs for myelofibrosis.
- Clinical regression of squamous Cell carcinoma and keratoacanthomas in a patient treated with a hypomethylating agent.
- Management of cytopenias in patients with myelofibrosis treated with ruxolitinib and effect of dose modifications on efficacy outcomes.
- Prognostic interaction between thrombocytosis and JAK2 V617F mutation in the WHO subcategories of myelodysplastic/myeloproliferative Disease-unclassifiable and refract...
- Nilotinib cardiac toxicity: should we still be concerned?
- Long term follow-up of allogeneic stem cell transplantation in patients with myelodysplastic Syndromes using busulfan, cytosine arabinoside, and cyclophosphamide.
- Recurrent deep vein thrombosis and pulmonary embolism in a young man with Klinefelter''s Syndrome and heterozygous mutation of MTHFR-677C>T and 1298A>C.
- Imatinib and Panax ginseng: a potential interaction resulting in Liver toxicity.
- Expression of natural killer receptors in T- and NK-Cells: comparison of healthy individuals, patients with prior stem Cell transplant, and patients undergoing chemoth...
- Resolution of rheumatoid arthritis symptoms with imatinib mesylate.
- Practical considerations for the management of patients in the tyrosine kinase inhibitor era.
- Prospect of JAK2 inhibitor therapy in myeloproliferative neoplasms.
- Myeloproliferative disorder with eosinophilia and ETV6-ABL gene rearrangement: efficacy of second-generation tyrosine kinase inhibitors.
- Treatment strategies in myelodysplastic Syndromes.
- Use of hypomethylating agents in myelodysplastic Syndromes.
- Establishment of baseline toxicity expectations with standard frontline chemotherapy in Acute myelogenous leukemia.
- Congestive heart failure is a rare event in patients receiving imatinib therapy.
- Emerging safety issues with imatinib and other Abl tyrosine kinase inhibitors.
- Optimal initial therapy for patients with newly diagnosed chronic myeloid Leukemia in chronic phase.
- In reply to 'Cardiotoxicity of the Cancer therapeutic agent imatinib mesylate'.
- The role of decitabine in the treatment of myelodysplastic Syndromes.
- Agent Orange, prostate cancer irradiation and Acute promyelocyic leukemia (APL): is there a link?
- Granulocyte transfusion.
- Treatment of metastatic malignant melanoma.
- Chronic myelogenous Leukemia in T cell lymphoid blastic phase achieving durable complete cytogenetic and molecular remission with imatinib mesylate (STI571; Gleevec) t...
- Rigosertib versus best supportive care for patients with high-risk myelodysplastic Syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled,...
Procedures Preformed
- Plasmapheresis
Conditions Treated
- Acute Leukemia
- Anal and Rectal Cancer
- Anemia
- Antiphospholipid Syndrome (APS)
- View All
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- CMS Meaningful Use Stage 1 Certification
Education
-
Wayne State University School of Medicine -
Cairo University School of Medicine
Hospital
-
Froedtert Memorial Lutheran Hospital
Drug Facts
| NPI NUMBER | 1235206285 | |
| NPPES Provider LastName | ATALLAH | |
| NPPES Provider FirstName | EHAB | |
| NPPES Provider ZIPCode | 532263522 | |
| NPPES Provider State | WI | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 979.0 | |
| Distinct Opioid Count | 2.0 | |
| Opioid Claim Count | 30.0 | |
| Percent Opioid Claims | 3.06 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1235206285 |
| Last Name Of The Provider | ATALLAH |
| First Name Of The Provider | EHAB |
| View All |
Similar Doctors
|
Dr. Karen L. Dallas, MDCM
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Gilbert C. White II, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Lauren Wiebe, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Nicholas F. Geimer, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Robert B. Hall, MD |
|
|
Dr. Michael W. Schuetz, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. James P. Thomas, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Mary Eapen, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. J Frank Wilson, MD |
|
|
Marwan S. Al-Akasheh |